Article | November 22, 2021

Scalable AAV Purification Process For Gene Therapy

Source: Cytiva
iStock-1256322438-lab-research-scientist

Processes to produce a common viral vector for gene therapy – adeno-associated virus (AAV) – are in place, but there’s room to improve them. Here we focus on optimizing AAV purification to achieve high overall yields and efficiently remove empty capsids and other impurities.

We developed a purification process for AAV2 and AAV5 serotypes, based on scalable, cost-efficient, and robust filtration and chromatography-based processes. The steps include harvest by cell lysis, clarification, concentration and buffer exchange, affinity capture, and finally anion exchange polishing to reduce empty capsids.

Further, we developed a convenient Biacore™ surface plasmon resonance (SPR) assay for robust and accurate determination of AAV2 titer.

Read this article to see the results.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Drug Discovery Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: